Multiple Sclerosis (MS) is a central nervous system (CNS) chronic inflammatory demyelinating disease leading to various neurological disabilities. The disorder is more prevalent for women with a ratio of 3:2 female to male. Objectives: To investigate variation within the estrogen receptor 1 (ESR1) polymorphism gene in an Australian MS case-control population using two intragenic restriction fragment length polymorphisms; the G594A located in exon 8 detected with the BtgI restriction enzyme and T938C located in intron 1, detected with PvuII. One hundred and ten Australian MS patients were studied, with patients classified clinically as Relapsing Remitting MS (RR-MS), Secondary Progressive MS (SP-MS) or Primary Progressive MS (PP-MS). Also, 110 age, sex and ethnicity matched controls were investigated as a comparative group. No significant difference in the allelic distribution frequency was found between the case and control groups for the ESR1 PvuII (P = 0.50) and Btg1 (P = 0.45) marker. Our results do not support a role for these two ESR1 markers in multiple sclerosis susceptibility, however other markers within ESR1 should not be excluded for potential involvement in the disorder.
Introduction
Multiple Sclerosis (MS) is a chronic, inflammatory, demyelinating disease of the central nervous system (CNS) that predominantly affects young Caucasians, usually with an age of onset of 18 to 40 years old. Females account for approximately 60% of MS cases [1] . The CNS in MS sufferers is affected with patches of myelin degeneration resulting from multifocal inflammatory events. Myelin, which is composed of a lipid bilayer and proteins, forms the extended membrane of oligodendrocyte and insulates neurons to provide rapid conduction of the action potential along the axons. Sex steroid hormones are very important in pregnancy and interestingly, within the third trimester of gestation, MS sufferers show a remarkable and unexplained decrease in relapses [2] . In addition, estrogens are capable of immunomodulation. Estrogen has been shown to increase the expression of the Forkhead box P3 (FoxP3), a gene localized to the short arm of chromosome X. FoxP3 binds to the promoter of IL2 gene and suppress its expression. Also, FoxP3 suppresses the gene expression of INFg and interleukin 4 in naïve T cells [3] . Interestingly, the estrogen dependent Fox P3 has been found to be down-expressed in MS peripheral CD4 + CD25+ T cells [4] while estrogen E2
(17-beta-estradiol) increases the proliferation of CD4 + CD25+ [5] . Furthermore, in estrogen treated and pregnant mice, FoxP3 shows enhanced expression compared to controls [6] . Interestingly, estrogen biosynthesis is dependent on vitamin D receptor, a gene in which a polymorphism has been previously found to be positively associated with MS [7] and [8] . VDR has a direct action on estrogen biosynthesis specifically within the aromatase gene [9] .
Considering the potential significance of genes relating to estrogen in MS, we decided to investigate two polymorphisms in the ESR1 gene (with PvuII in intron 1 region and Btg1 in exon 8) for their potential involvement in MS susceptibility in an Australian MS population.
Methods

Subject groups
The participants of the study were unrelated and of Caucasian (Northern European) origin. The study protocol was approved by Griffith University's ethics committee for experimentation on humans. The test groups consisted of 110 MS patients and 110 controls, matched for ethnicity, sex and age (+/− 5 years). The MS population was obtained from patients from the Multiple Sclerosis Clinic at the Royal Brisbane and Women's Hospital, mainly from the South East Queensland region. All MS individuals were diagnosed using the 2005 revised McDonald criteria for multiple sclerosis [10] . The populations were all descendent from northern European parents, grand parents or great grand parents who came to Australia within the last 200 years. The population investigated did not contain any native Australians (Aboriginal or Torres Straight Island descent). This case group consisted of 75% women and 25% men and were subdivided into three groups according to the clinical course:
Relapsing-Remitting MS (RR-MS), Secondary Progressive MS (SP-MS) and Primary
Progressive MS (PP-MS) with frequencies of 42%, 37%, and 21% respectively. The control group was also obtained from the South East Queensland region through the Genomics Research Centre, Southport, with each control matched to an MS patient for the variables age (+/− 5 years), sex, and ethnicity. All individuals gave informed consent before participating in the research. Genomic DNA was extracted from peripheral blood leucocytes using a standard salting-out protocol.
Genotyping
Two polymorphisms were genotyped with two restriction fragment length polymorphisms (RFLPs) used to detect each variant. Intron 1 of ESR1 was investigated using the PvuII restriction enzyme to detect, at the nucleotide position 938, a T to C substitution. The second marker Btg1 was used to detect a polymorphism of ESR1 in the 3′ region of the gene specifically in Exon 8 to detect an A to G substitution. These polymorphic regions were amplified by standard, unlabeled oligonucleotides followed by restriction enzyme digestion corresponding to each RFLP. Oligonucleotide primers used for PvuII and Btg1 RFLP were: forward primer 5′ TGACACATGTTCTGTGTTGTCC3′; reverse 5′ CTGGTGCAGGTAGTATGTTTTT 3′; and for Btg1 RFLP were: forward 5′ CTGTGTCTTCCC ACCTACAG 3′ and reverse 5′ CGTGTGGGAGCCAGGGAGCT 3′. For detection of the ESR1 intronic marker, 20-30 ng genomic DNA was amplified with 1 X polymerase chain reaction (PCR) buffer, 3 mM MgCl 2 , 0.2 mM each dNTP, 0.2 µM each primer and Taq polymerase in a 20-µL final volume on a Corbett (Sydney, Australia) PC-960 thermocycler. Cycles consisted of a 2-min denaturation at 94 °C followed by 40 cycles of 94 °C for 1 min and 56 °C for 30 s and 72 °C for 30 s then a final extension at 72 °C for 2 min. PCR products were digested with PvuII (1 U at 37 °C) and electrophoresed on 5% ethidium bromide stained agarose gels. Genotypes were denoted as TT (239 bp 
Statistical analysis
Genotype and allele frequencies for the ESR variants were calculated from observed genotype counts. As a statistical control for systematic genotyping error and population stratification, the expected genotype proportions according to the Hardy-Weinberg law were calculated and compared to observed genotypes. Genotype and allele frequencies were initially assessed for association with MS using conventional contingency table analyses incorporating the standard chi-squared test for independence. This analysis produces a χ 2 statistic with one or two degrees of freedom and corresponding P-values for allele and genotype distributions, respectively. 
Results
The genotype and allele frequencies for all the two variants are shown in Table 1 and Table 2 . All genotypes for the case-control association studies conformed to Hardy-Weinberg equilibrium (HWE) expectations (P > 0.05) in both case and control groups. The allele and genotype frequencies for both the PvuII (P = 0.50 and P = 0.63, respectively) and Btg1 (P = 0.45 and P = 0.75, respectively) variants, showed no significant difference between the MS population and the control population. In our investigation, we showed no association of these ESR1 markers with RR-MS, PP-MS and SP-MS.
Discussion
The aim of this study was to investigate two sequence polymorphisms in the ESR1 gene, PvuII and Btg1, for their involvement in MS susceptibility within an Australian cohort. For both markers, genotypes were investigated in 110 MS patients and 110 matched controls. In this present study, we report no association of these markers with MS. Both genotype and allele frequency distributions for both ESR1 markers showed no significant differences between the MS and control populations. In our investigation, we also showed no association of these ESR1 markers with RR-MS, PP-MS and SP-MS. Although these results were clearly non-significant, the cohort of MS individuals used in this study is of moderate size and further investigation with larger cohorts should be considered to determine more specifically whether ESR variants have a low or moderate effect on disease susceptibility.
In MS, women are more affected than men with a ratio of 3:2 and this female prevalence is also encountered in the experimental allergic encephalomyelitis (EAE) MS animal model [11] . A striking point found in MS and observed as well in rheumatoid arthritis (RA) is the reduction of disease linked symptomatology during pregnancy [12] . In contrast, after parturition, flares of the disease are recorded in affected women [2] . Proinflammatory cytokines induce local inflammation in the CNS leading to CNS demyelination. Such cytokines can be modulated in expression by steroid hormones with direct immunosuppression observed in EAE MS like animal models [13] . Estrogen receptor polymorphic variants have been previously investigated in MS but with conflicting results. Two studies gave positive association of the ESR1 PvuII polymorphism with MS [14] and [15] while a more recent study gave negative association findings for the ESR1 PvuII polymorphism [16] . In this present report we show no association of the PvuII marker in the ESR1 gene with MS in an Australian population reinforcing previously negative results by Savettieri et al. [16] . However, we cannot exclude the possibility that other markers within ESR1 could be involved in MS susceptibility. Indeed, recent evidence suggests that estrogens could influence the gender difference observed in MS and other neurological disorders [17] . Studies on animal models have shown estradiol (E2) dose dependent inhibition of clinical signs of EAE when E2 was given a week before EAE induction [18] and [19] . Also of interest, several positive association results have been found between estrogen receptor variants and other autoimmune disorders including lupus and rheumatoid arthritis [20] and [21] as well as with the Parkinson neurodegenerative disease [22] . In addition, an association has also been found between the PvuII ESR1 polymorphism and the HLA DR2 allele [15] and a recent Japanese study found an independent positive association of the ESR1 PvuII T allele with HLA-DRB1 1511 allele, an allele associated with MS development [23] .
